Artivion posts $7.9M loss on $123.8M sales as AMDS uptake begins

Artivion, which sells devices for aortic disease, reported 9% year-on-year revenue growth to $123.8M for the quarter, in results published on 5 November 2026. The company named its On-X heart valve products and its stent grafts as the main drivers.

Profit did not keep pace with sales. Artivion recorded a net loss of $7.9M, and adjusted EBITDA came in below the level of the same quarter a year earlier. The material available does not explain what drove the loss or say how large the EBITDA decline was, so the extent of the margin pressure is not clear.

For the full year, Artivion now expects revenue of $484M to $492M, an $8M span. The information reviewed does not say what range it replaced, so the direction of the change cannot be judged here.

The company also reported that US implants of its AMDS device rose after the product received premarket approval (PMA) from the US regulator. As context, PMA is the FDA's most demanding route for high-risk devices, and approval is the point at which a company can begin selling in the US market. Artivion did not provide AMDS sales figures in the material reviewed.

Next on the calendar is a US launch of NEXUS, planned for January 2027. No details on the product's indication, pricing or rollout plan were available.